Listar por autoría "Rojo, Federico"

Ordenar por:Orden:Resultados:

  • A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition
    Vincent, Theresa; Neve, Etienne P.A.; Johnson, Jill R.; Kukalev, Alexander; Rojo, Federico; Albanell Mestres, Joan; Pietras, Kristian; Virtanen, Ismo; Philipson, Lennart; Leopold, Philip L.; Crystal, Ronald G.; García de Herreros, Antonio; Moustakas, Aristidis; Petterson, Ralf F.; Fuxe, Jonas (Nature Research, 2009)
    Epithelial-mesenchymal transition (EMT) is essential for organogenesis and is triggered during carcinoma progression to an invasive state. Transforming growth factor-beta (TGF-beta) cooperates with signalling pathways, ...
  • Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    Colomer, Ramon; Aranda-Lopez, Ignacio; Albanell Mestres, Joan; García-Caballero, Tomás; Ciruelos, Eva; Lopez-García, M. A.; Cortés, Javier; Rojo, Federico; Martín, M.; Palacios-Calvo, J. (SpringerOpen, 2018)
    This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish ...
  • CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer
    Luque, Melani; Cristóbal, Ion; Sanz Álvarez, Marta; Santos, Andrea; Zazo, Sandra; Eroles, Pilar; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; García-Foncillas, Jesús; Rojo, Federico (MDPI, 2022)
    Together with its reported ability to modulate AKT phosphorylation (p-AKT) status in several tumor types, the oncoprotein CIP2A has been described to induce breast cancer progression and drug resistance. However, the ...
  • Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
    Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.
    Pavlovic, Milica, 1985-; Arnal-Estapé, Anna ; Rojo, Federico; Bellmunt, Anna ; Tarragona, Maria ; Guiu, Marc; Planet, Evarist; Garcia-Albéniz, Xabier; Morales, Mònica; Urosevic, Jelena ; Gawrzak, Sylwia ; Rovira Guerín, Ana; Prat, Aleix; Nonell Mazelón, Lara; Lluch, Ana; Jean-Mairet, Joël ; Coleman, Robert ; Albanell Mestres, Joan; Gomis, Roger R. (Oxford Open , 2015)
    BACKGROUND: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest. METHODS: A de novo unbiased ...
  • Expression of phosphorylated BRD4 is markedly associated with the activation status of the PP2A pathway and shows a strong prognostic value in triple negative breast cancer patients
    Sanz Álvarez, Marta; Cristóbal, Ion; Luque, Melani; Santos, Andrea; Zazo, Sandra; Madoz-Gúrpide, Juan; Caramés, Cristina; Chiang, Cheng-Ming; García-Foncillas, Jesús; Eroles, Pilar; Albanell Mestres, Joan; Rojo, Federico (MDPI, 2021)
    The bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extra-terminal domain (BET) protein family, has emerged in the last years as a promising molecular target in many tumors including breast cancer. ...
  • FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors.
    Carracedo, Alma; Egervari, Kristof; Salido, Marta; Rojo, Federico; Arumí, Montserrat; Corominas Torres, Josep Maria; Corzo, Cristina; Tusquets Trias de Bes, Ignacio; Espinet Solà, Blanca; Rovira Guerín, Ana; Albanell Mestres, Joan; Szollosi, Zoltan; Serrano Figueras, Sergi; Solé Ristol, Francesc (BioMed Central, 2009)
  • FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth.
    Slebe Concha, Juan Felipe, 1981-; Rojo, Federico; Vinaixa, Maria; García-Rocha, Mar; Testoni, Giorgia; Guiu, Marc; Planet, Evarist; Samino, Sara; Arenas, Enrique J.; Beltran Marqués, Antoni; Rovira Guerín, Ana; Lluch, Ana; Salvatella, Xavier; Yanes, Oscar; Albanell Mestres, Joan; Guinovart, Joan J. (Joan Josep), 1947-; Gomis, Roger R. (Nature Publishing Group, 2016)
    The mechanisms that allow breast cancer (BCa) cells to metabolically sustain rapid growth are poorly understood. Here we report that BCa cells are dependent on a mechanism to supply precursors for intracellular lipid ...
  • GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain
    Martín, Miguel; Guerrero-Zotano, Ángel; Montero, Ángel; Jara, Carlos; Filipovich, Elena; Rojo, Federico; Moreno, Fernando; García-Sáenz, Jose Ángel; Alés, Jose Enrique; Chacón, José Ignacio; Cruz, Josefina; Giménez, Julia; Cruz-Merino, Luis; Algara López, Manuel-Ignacio; Santisteban, Marta; López Tarruella, Sara; GEICAM Spanish Breast Cancer Group Steering Committee (Oxford University Press, 2020)
    Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARS-CoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed ...
  • Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
    Zazo, Sandra; González-Alonso, Paula; Martín-Aparicio, Ester; Chamizo, Cristina; Cristóbal, Ion; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Eroles, Pilar; Lluch, Ana; Madoz-Gúrpide, Juan; Rojo, Federico (e-Century Publishing, 2017)
    Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to ...
  • HER2 as a target in invasive urothelial carcinoma
    Bellmunt Molins, Joaquim, 1959-; Werner, Lillian; Bamias, Aristotle; Fay, André P.; Park, Rachel S.; Riester, Markus; Selvarajah, Shamini; Barletta, Justine A.; Berman, David M.; Muga, Silvia de; Salido, Marta; Gallardo, Enrique; Rojo, Federico; Guancial, Elizabeth A.; Bambury, Richard; Mullane, Stephanie A.; Choueiri, Toni K.; Loda, Massimo; Stack, Edward; Rosenberg, Jonathan E. (Wiley, 2015)
    We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ...
  • High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
    Cañadas, Israel; Taus, Álvaro; González, Iria; Villanueva, Xavie; Gimeno, Javier; Pijuan, Lara; Dómine, Manuel; Sánchez-Font, Albert; Vollmer, Ivan; Menéndez, Silvia; Arpí, Oriol; Mojal, Sergi; Rojo, Federico; Rovira, Ana; Albanell, Joan; Arriola Aperribay, Edurne (Impact Journal, 2014)
    We have previously shown that Met activation through the hepatocyte growth factor (HGF) increases tumorogenesis, induces epithelial-to-mesenchymal transition (EMT) and chemoresistance in SCLC. We sought to evaluate circulating ...
  • Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion
    Berghoff, Anna S.; Bellosillo Paricio, Beatriz; Caux, Christophe; de Langen, Adrianus; Mazieres, Julien; Normanno, Nicola; Preusser, Matthias; Provencio, Mariano; Rojo, Federico; Wolf, Jurgen; Zielinski, Christoph C. (BMJ Publishing Group, 2019)
    The introduction of targeted treatments and more recently immune checkpoint inhibitors (ICI) to the treatment of metastatic non-small cell lung cancer (NSCLC) has dramatically changed the prognosis of selected patients. ...
  • Inhibition of specific NF-KB activity contributes to the tumor suppressor function of 14-3-3omega in breast cancer
    Inglés Esteve, Julia; Morales, Mònica; Dalmases Massegú, Alba, 1982-; Garcia Carbonell, Ricard; Jené i Sanz, Alba, 1984-; López Bigas, Núria; Iglesias Coma, Mar; Ruiz Herguido, Cristina; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; Gomis, Roger R.; Bigas Salvans, Anna; Espinosa Blay, Lluís (Public Library of Science (PLoS), 2012)
    14-3-3σ is frequently lost in human breast cancers by genetic deletion or promoter methylation. We have now investigated the involvement of 14-3-3σ in the termination of NF-κB signal in mammary cells and its putative role ...
  • Interplay between Natural killer cells and Anti-HER2 antibodies: Perspectives for breast cancer immunotherapy
    Muntasell i Castellví, Aura, 1972-; Cabo, Mariona, 1991-; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; López-Botet, Miguel (Frontiers, 2017)
    Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy ...
  • Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
    Remon, Jordi; García-Campelo, Rosario; Álava, Enrique de; Vera, R.; Rodríguez Peraltó, José Luís; Rodríguez-Lescure, Álvaro; Bellosillo Paricio, Beatriz; Garrido, P.; Rojo, Federico; Álvarez-Alegret, R. (Springer, 2020)
    The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing considerably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of ...
  • MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma
    Pattanayak, Birlipta; Garrido Cano, Iris; Adam-Artigues, Anna; Tormo, Eduardo; Pineda, Begoña; Cabello, Paula; Alonso, Elisa; Bermejo, Begoña; Hernando, Cristina; Martínez, María Teresa; Rovira, Ana; Albanell Mestres, Joan; Rojo, Federico; Burgués, Octavio; Cejalvo, Juan M.; Lluch, Ana; Eroles, Pilar (Frontiers, 2020)
    Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) ...
  • miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer
    Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell Mestres, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar (MDPI, 2023)
    Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication ...
  • Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
    Conde, Esther; Rojo, Federico; Gómez, Javier; Enguita, Ana Belen; Abdulkader, Ihab; González, Ana; Lozano, Dolores; Mancheño, Nuria; Salas, Clara; Salido Galeote, Marta; Salido, Eduardo; Álava, Enrique de (BMJ Publishing Group, 2022)
    The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses ...
  • mTOR inhibition and T-DM1 in HER2-positive breast cancer
    Casadevall Aguilar, David; Hernández Prat, Anna, 1984-; García-Alonso, Sara; Arpí Llucià, Oriol; Menéndez, Silvia; Qin, Mengjuan; Guardia Valenzuela, Cristina, 1990-; Morancho Armisen, Beatriz; Sánchez-Martín, Francisco Javier; Zazo, Sandra; Gavilán, Elena; Sabbaghi Mehrjardi, Mohammad Ali; Eroles, Pilar; Cejalvo, Juan M.; Lluch, Ana; Rojo, Federico; Pandiella, Atanasio; Rovira, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2022)
    In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR ...

Buscar en DSpace

Listar

Mi cuenta

Con colaboración de Cumplimos Participamos